Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for
use in treating acute decompensated heart failure and heart failure associated
with muscular dystrophy.

• OUR PEOPLE
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC & MEDICAL ADVISORY BOARD
• PRODUCT BACKGROUND
• INDICATIONS
• CONTACT

NEWS

Phrixus Pharmaceuticals, inc. announces $890,000 in NIH funding for its programs in Duchenne Muscular Dystrophy and Heart Failure

Awards to fund respiratory studies for Carmeseal™ in Duchenne muscular dystrophy and mechanism of action studies in heart failure

read more

CLINICAL TRIALS

Phrixus has concurrence with FDA on the following:

• First clinical study under the IND in stable heart failure patients – dose escalation design
• Agreement for exploratory Duchenne Muscular Dystrophy study under same IND

©2010 Phrixus Pharmaceuticals Inc. All Rights Reserved

1600 Huron Parkway, Building 520, 2nd Floor, Ann Arbor, MI 48109 (734) 358-9015 thomas.collet@phrixuspharmaceuticals.com